Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T12:50:45.952Z.
Calculation as of: 2026-10-06T12:50:45.952Z.
Quote observation: 2026-10-05T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3f32b4356dd318fc5fc0a902c875af90b1a094ceb52f500a6b854293a5898a5a
PE RATIO
N/A
Basel Medical Group Ltd Ordinary Shares
Market Cap
$4.96M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.42M
PE Ratio
N/A
TTM Avg
79.42
3Y Avg
79.42
5Y Avg
79.42
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Basel Medical Group Ltd Ordinary Shares (BMGL) | $4.96M | N/A | N/A | N/A | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.99M | N/A | N/A | N/A | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.85M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.79M | N/A | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $5.21M | N/A | 1.64 | 1.64 | 1.64 |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.46M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.42M | N/A | 79.42 | 79.42 | 79.42 |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.41M | N/A | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.54M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
